Use of Thromboprophylaxis for Central Venous Access Devices in Patients with Sickle Cell Disease: A Survey of Canadian Providers
Kristine Matusiak(Thrombosis and Atherosclerosis Research Institute), Kevin H.M. Kuo(University Health Network), Madeleine Verhovsek(McMaster University), Stéphanie Forté(University Health Network), Jameel Abdulrehman(University Health Network)
Cited by 2
Related Papers
A Phase 3 Trial of Luspatercept in Patients with Transfusion-Dependent β-Thalassemia
|New England Journal of Medicine|2020|320
Clinical spectrum of pyruvate kinase deficiency: data from the Pyruvate Kinase Deficiency Natural History Study
|Blood|2018|165
Safety and Efficacy of Mitapivat in Pyruvate Kinase Deficiency
|New England Journal of Medicine|2019|162
Prophylactic transfusion for pregnant women with sickle cell disease: a systematic review and meta-analysis
|Blood|2015|129
Depression, Depression Treatments, and Risk of Incident Dementia: A Prospective Cohort Study of 354,313 Participants
|Biological Psychiatry|2022|113